AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU
IMFINZI combinations show meaningful overall survival in liver and biliary tract cancers LYNPARZA combined with abiraterone will demonstrate clinical benefit regardless of biomarker status in metastatic castration-resistant prostate cancer WILMINGTON, ...
